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Low dose angiotensin converting enzyme inibition and glomei-ular
permselectivity in renal transplant recipients. In this study, we deter-
mined the fractional clearance of neutral polydisperse dextrans (®) and
monodisperse dextran sulfate (O) to describe glomerular size and
charge selectivity in 25 renal transplant recipients with proteinuria.
Thirteen were treated with low dose lisinopril for six months (group 1) and
12 patients without ACE inhibitor therapy formed group 2. Mean arterial
blood pressure was stable (group 1, 112 4; group 2, 109 2 mm Hg at
baseline and after 6 months) whereas creatinine clearance, glomerular
filtration rate and renal plasma flow decreased nonsignificantly but were
comparable at any time. Lisinopril treatment lowered filtration fraction(22 2 vs. 19 2%, P = 0.07) whereas no change was seen in group 2
(20 2%). The fractional protein excretion (mg urinary protein per
day/mi creatinine clearance per day) was stable in group 1, but significantly
increased in group 2. The same pattern was found for ® larger than 56
A. ®s was stable and consistently elevated in both groups at any time. We
conclude that low dose ACE inhibitor treatment in proteinuric renal
transplant recipients stabilizes glomerular size selectivity independently of
its systemic hemodynamic effects.
Chronic kidney transplant failure (CKTF) is an increasing cause
of terminal renal insufficiency. Its pathogenesis is incompletely
understood; however, immunological as well as nonimmunologi-
cal factors seem to contribute to patient mortality [1—3]. Several
clinical and histopathological similarities between chronic native
kidney disease and CKTF have been noted, and among them
glomerular proteinuria is one of the most important [1]. Recently
we were able to show that persistant proteinuria is an independent
risk factor for excretory allograft function loss [4]. Glomerular
proteinuria is a consequence of an alteration of glomerular
permselective properties. The transport of macromolecules (and
thus proteins) through the glomerular filter is determined by their
molecular size, charge and shape [5]. As endogenous proteins
undergo a variable rate of tubular reabsorption they cannot be
used directly to elucidate the characteristics of the glomerular
filter. Therefore, tubular inert exogenous polymers are used for
this purpose. The sieving coefficient (s), the final urine-to-plasma
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concentration ratio of these markers, divided by the urine-to-
plasma ratio of an ideal marker for glomerular filtration is
equivalent to the Bowman's space-to-plasma concentration ratio.
It is therefore the most direct measure of the intrinsic barrier
properties of the glomerular capillary wall. Neutral dextrans of
broad size distribution serve as markers for glomerular size
selectivity [6]. Negatively-charged dextran sulfate, on the contrary,
is being used to determine glomerular charge selectivity [7]. We
applied these techniques to investigate glomerular perrnselective
properties in patients late after kidney transplantation, who were
diagnosed with proteinuria before and after a six-month treat-
ment period with the ACE inhibitor, lisinopril. in a low dose
regimen. The subjects were compared to a matched group of
patients who did not have a blockade of the renin-angiotensin
system. ACE inhibitors have been shown to reduce proteinuria in
a variety of native kidney diseases and in patients after transplan-
tation [8—11]. The exact effect of this treatment on parameters of
glomerular permselectivity, however, have been described so far
only in animal experiments [12]. Furthermore, we wanted to test
whether a renal effect of ACE inhibition could be achieved
without interference with systemic hemodynamics.
METHODS
Patients
Twenty-five post-transplant renal patients with proteinuria > 1
day were recruited from our outpatient clinic. The renal trans-
plantation was performed at least six months prior to the baseline
evaluation, and all patients had a stable allograft function as
determined by serum creatinine during the six months preceding
the study. Immunosuppression consisted of triple drug therapy
(prednisolone, eyclosporine A and azathioprine) in eight group 1
and seven group 2 patients. The remainder of the patients were on
prednisolone/cyclosporine A treatment only. Immunosuppression
was unchanged throughout the study period. Cyclosporine A
trough levels were identical in both groups at baseline and after
six months. Thirteen patients (6 male, 7 female, mean time after
transplantation 47 12 months) received the ACE inhibitor
lisinopril in a mean dose after 6 months of 6.2 2.1 mg/day.
Native kidney disease leading to terminal renal insufficiency was
identified by renal biopsy in five subjects: chronic interstitial
nephritis, focal and segmental glomerulosclerosis, membranous
nephropathy, diabetic renal disease and IgA nephropathy. In this
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group 12 patients underwent allograft biopsy. Signs of cyclospor-
me A toxicity were found in eight and chronic transplant rejection
in six cases. In three allografts membranous nephropathy was
additionally detected. In 12 additional patients (7 male, 5 female,
mean time after transplantation 55 14 months) no change in the
antihypertensive therapy was made. Native kidney biopsy was
performed in five patients, which revealed IgA nephropathy and
chronic interstitial nephritis in two patients each, and membra-
nous nephropathy in one subject. Seven patients also had an
allograft biopsy; cyclosporine A toxicity was found in three and
chronic rejection in four cases. Membranous nephropathy was
additionally diagnosed in two subjects. The groups were matched
for time after transplantation, creatinine clearance, blood pres-
sure and proteinuria. Additional antihypertensive therapy was
necessary in nine patients in group 1 (beta blocking agents in 6,
alpha blocking agents in 5, and calcium antagonists in 4) and in
eight group 2 patients (beta blocking agents in 4, alpha blocking
agents in 6, and calcium antagonists in 3). This was unchanged
throughout the study period.
Functional studies
Functional studies were performed as given in complete detail
elsewhere at baseline and after six months of therapy [13]. Before
clearance studies, the patients were told to void completely and an
oral water load of 10 mI/kg body wt was given to ensure high urine
output. A 30 minute infusion of a 1:5 Dextran 40/Detran 70
mixture at a total dose of 130 mg/kg body wt was administered.
Dextran 40 and Dextran 70 (Ebewe, Unterach, Austria) are
clinical preparations of polydisperse dextrans with mean molecu-
lar weights of 40,000 and 70,000, respectively. Patients with a
history of penicillin allergy were excluded from the study to
eliminate risk factors for dextran allergy, and no adverse events
occurred during the study. This mixture allowed a determination
of the clearance of dextrans up to a radius of 60 A. lothalamate
(Conray 60®; Cl Pharma, Linz, Austria) and para-aminohippuric
acid (PAH) (Nephrotest®; BAG, Lich, Germany) were infused
continuously after a bolus for determination of the glomerular
filtration rate and renal plasma flow. As the extraction of PAH is
incomplete in advanced renal failure, an extraction rate of 0.7 was
assumed in patients with GFR < 40 mi/mm [14]. A dextransulfate
preparation (Ueno Fine Chemicals, Osaka, Japan) was tritiated
(New England Nuclear Corp., Boston, MA, USA), as a dose in the
toxic range of the unlabeled preparation would have to be infused
to achieve plasma concentrations within the assayable range. The
preparation was checked for free radioactivity by gel permeation
chromatography. A total of 300 rCi was infused as a bolus within
five minutes after the neutral dextran infusion was finished.
After an equilibration period of 90 minutes, two clearance
periods (30 mm each) were performed. Blood was drawn at the
beginning and end of each period and an analysis was done on
pooled plasma. Urine was collected throughout the clearance
periods and urinary losses were replaced immediately by oral
drinking of tap water.
Analytical methods
Neutral dextran size separation of plasma and urine samples
from 30 to 60 A was performed using a size exclusion HPLC
(Jasco International Co. Ltd., Tokyo, Japan). The concentration
of the dextran fractions within a size range from 30 to 60 A was
measured using an online refractive index detector.
The concentration of tritiated dextran sulfate in urine and
plasma was measured by liquid scintillation counting (Beckman
Instruments, Inc., Fullerton, CA, USA). As reported previously,
dextran sulfate is significantly bound to plasma proteins [12].
Separation of bound and free dextransulfate in plasma samples
was performed using gel permeation chromatography and only
the unbound fraction was used to calculate the dextransulfate
clearance. In urine even in nephrotic patients < 2% of dextran
sulfate are protein bound, and therefore total radioactivity was
used for calculation.
Analysis of PAH and iothalamate was performed using a
reversed-phase HPLC system (Jasco International Co. Ltd) as
described by Morelli et al [151.
Blood pressure was measured by the Riva Rocci method after
the patients had been resting for 10 minutes. The measurement
was repeated at least one or more times until a stable value was
obtained. Cyclosporine A trough levels were determined using a
specific monoclonal antibody (Cyclotrac®; Incstar, Stillwater,
MN, USA).
The fractional clearance theta (0) of neutral dextrans and
dextransulfate was calculated using the equation
Clearance marker
Theta marker (OM) = Clearance iothaiamate
The fractional protein excretion was calculated as the mg
protein in 24-hour urine divided by the ml creatinine clearance
per day.
Statistics
All results are expressed as mean SEM. For statistical analysis
urinary protein excretion and fractional clearance values for
neutral dextrans were log transformed. The two-tailed Student's
t-test for paired data was used to assess differences in one group,
and the Student's t-test for unpaired data was used for comparison
between the two groups. A P value < 0.05 was considered
statistically significant.
The study was approved by the local human subject committee,
and a written informed consent was obtained from every patient
before the study.
RESULTS
Serum creatinine, creatinine clearance (as determined from the
24-hr urinary sample), glomerular filtration rate, renal plasma
flow and filtration fraction were similar in both groups at baseline.
Excretory allograft function slightly deteriorated during the six
month period in both groups. Filtration fraction was stable in
group 2 whereas lisinopril lowered the filtration fraction from
22 2% to 19 2% in group 1, although this reduction did not
reach the level of significance (P = 0.07; Table 1).
Mean arterial blood pressure (MAP) was similar in both groups
at any time point and was stable throughout the six month study
period (112 4 mm Hg in group 1 and 109 2 mm Hg in group
2 at baseline and at 6 months, respectively).
Data on glomerular permeability function are given in Table 2
and in Figures 1 and 2. Twenty-four-hour urinary protein excre-
tion was slightly higher at baseline in the lisinopril group (5.8
1.1 vs. 3.8 0.77 g/day in group 2, P = 0.15). After six months the
urinary protein excretion had decreased to 3.3 0.6 g/day in
group 1, whereas an increase was noted in group 2 (5.6 1.22
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Table 1. Excretory allograft function and renal hemodynamics in the
two study groups
Time period Lisinopril Control
Serum creatinine mg% baseline 2.32 0.16 2.48 0.23
6 months 2.72 0.35 2.77 0.33
Creatinine clearance mi/mm baseline 41 4 43 5
6months 37±5 40±5
GFR mi/mm baseline 39 4 36 5
6months 33±5 29±4
RPF mi/mm baseline 187 21 179 25
6 months 179 15 146 20
FF % baseline 22 2 20 2
6months 19±2 20±2
Table 2. Glomerular permeability in the two study groups
Time period Lisinopril Control
®ro, mg/mi baseline 0.121 0.03 0.078 0.026
6 months 0.093 0.031 0.113 0.026a
baseline 0.69 0.05 0.75 0.04
6 months 0.75 0.04 0.79 0.06
P < 0.05 baseline vs. 6 months
I I I I I I I30 34 38 42 46 50 54 58 62
Dextran radius, A
Fig. 1. Fractional clearance of neutral dextrans of broad size distribu-
tion in patients on low dose lisinopril therapy at baseline (•) and after six
months (0).
0.001- I I
30 34 38 42 46
Dextran radius, A
Fig. 2. Fractional clearance of neutral dextrans of broad size distribu-
tion in control patients without low dose lisinopril therapy at baseline (U)
and after six months (LI).
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g/day). When the fractional protein excretion was calculated, this
value was stable in group 1 (0.121 0.03 mg protein/mi creatinine
clearance at baseline vs. 0.093 0.031 mg/mi, P 0.43) whereas
it significantly increased in group 2 (0.078 0.021 vs. 0.113
0.026 mg/mi, P = 0.03). However, neither total protein excretion
nor fractional protein excretion were different between the two
groups at any time point. The fractional clearance of dextransul-
fate was similar and elevated in both groups at baseline and after
six months when compared to the values obtained in normal
controls, indicating a loss of glomerular charge selectivity as one
of the pathogenetic factors of proteinuria in these patients
0.69 0.05 in group 1 vs. 0.75 0.04 in group 2 at baseline, and
after 6 months 0.75 0.04 vs. 0.79 0.06, respectively; normal
value obtained in 12 healthy volunteers, 0.57 0.04 [13]). The
fractional clearance values of neutral dextrans of a broad size
distribution as a measure for glomerular size selectivity are given
in Figure 1 and Figure 2. The values were similar between the two
groups at baseline. However, in untreated patients glomerular size
selectivity deteriorated significantly over the six month period, as
evidenced by a significant increase of the fractional clearance of
dextrans larger than 56 A. In contrast, there was a small but
nonsignificant improvement in the lisinopril group.
DISCUSSION
Chronic renal transplant failure is usually accompanied by
glomerular proteinuria. Recently we were able to demonstrate
that proteinuria in this condition is due to a defect in glomerular
permselective properties [13, 16]. Low grade proteinuria is char-
acterized by a defect in glomerular charge selectivity, whereas
development of nephrotic range proteinuria is associated with an
impairment of glomerular size selectivity. This sequence of events
is similar to that observed in chronic native kidney diseases like
diabetic nephropathy [171, and most likely in any condition that
can be subsummarized under the term secondary focal and
segmental glomerulosclerosis.
50 54 58 62
Most studies on the effect of ACE inhibitor therapy on
proteinuria in kidney disease including renal transplant failure
have shown a reduction of protein excretion [8—11] with effects on
charge and size selectivity. Diabetic microathuminuria has been
shown to be due to an isolated defect of glomerular charge
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selectivity [17, 181 and ACE inhibitors have been successfully used
in this condition [191. In patients with diabetic nephropathy and
nephrotic range proteinuria, Morelli et al were able to show that
blockade of the renin-angiotensin system restores glomerular size
selectivity [15]. No human study has investigated the effects of
ACE inhibition on both components of permselectivity to date. In
an animal model of chronic renal disease and nephrosis, we
demonstrated that angiotensin II receptor blockade restores
glomerular size selectivity without affecting charge selectivity [121.
In our present study, proteinuria increased in the control group
whereas low dose lisinopril did not reduce proteinuria and only
stabilized size selectivity. In contrast to most published studies,
ACE inhibitor treatment in our population had absolutely no
effect on systemic blood pressure and the lack of a reduction of
proteinuria could be due to this factor. Although the reduction of
filtration fraction did not reach the level of statistical significance,
it still strongly suggests a beneficial intrarenal hemodynamic effect
of the drug. Another explanation for the fact that proteinuria did
not decrease might be that this was a long-term study in a
progressive disease. An early reduction of proteinuria with a
gradual increase thereafter could well also result in identical
24-hour urinary protein excretion values at six months. The exact
mechanisms of how ACE inhibitors affect permselectivity remain
speculative. The studies of Gansevoort, de Zeeuw and de Jong
[18], however, indicate that factors other than hemodynamic
effects might be involved.
One might argue that the magnitude of the observed differ-
ences in our study is small and therefore the clinical significance
is unclear. We have collected data on 469 transplant recipients in
our outpatients clinic (detailed in [4]) and divided these patients
into two groups. Urinary protein excretion increased in 293
subjects during a period of two years (from 0.42 0.12 to 1.27
0.13 glday) but remained stable or decreased in the other 176
(proteinuria at baseline 0.91 0.13 vs. 0.43 0,08 g/day after two
years). Creatinine clearance values were similar in the beginning
(60 1 vs. 61 2 mI/mm) but were significantly lower in patients
with an increase in proteinuria after two years (50 1 vs. 55 1
ml/min). Hence, in this large patient group a rather small increase
in proteinuria was accompanied by a significant reduction of
excretory allograft function.
In summary, we conclude that low dose ACE inhibitor treat-
ment in proteinuric renal transplant recipients stabilizes glomer-
ular size selectivity independently of its systemic hemodynamic
effects.
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